



ORCA-010 SHOWS IMPRESSIVE FIRST-LINE PROSTATE CANCER DATA.

's-Hertogenbosch, the Netherlands

ORCA-010, an oncolytic adenovirus, has demonstrated strong single-agent antitumor activity in the first patient treated with the product. MRI data is impressive reflecting significant decrease in prostate volume returning to normal size, as well as an ongoing decrease in PSA.

In a phase I/II trial evaluating the safety and tolerability of intra-tumoral administration of ORCA-010 in treatment-naïve patients with localized prostate cancer, six-months data are available on the first patient in the study, following the lowest studied single dose.

MRI images revealed that within six months after intra-tumoral administration of the single dose, the prostate volume in this treatment-naïve patient with localized prostate cancer had decreased by a factor of almost 2. In fact, ORCA was encouraged that the patient's prostate volume had virtually returned to a normal size considering the age of the patient. The decrease in prostate volume is also consistent with the PSA decrease.

Even more interesting was that less areas with tumor tissue are reported. At screening 3/6 prostate lobes showed tumors, whereas at 6 months after injection of ORCA-010 MRI images showed that the tumor was seen in only one lobe of the prostate. Data is impressive to the Principal Investigator noting response never seen before with hormonal therapy. Especially since all was seen in less than six months of injection the obtained data provide strong indication of a significant single-agent antitumor activity of ORCA-010.

ORCA-010 was very well-tolerated, with only a transient mild increase in body temperature and flu-like symptoms.

Due to the global COVID-19 health pandemic, clinical trials have been delayed for four months, however, ORCA is pleased to announce that the trials have resumed and that the second patient has been dosed on July 15, 2020.

For more information please visit <http://www.orca-therapeutics.nl/>

Please contact

Kees Groen, CEO

+31 653648230

info@ORCA-therapeutics.com